Table 2.
Univariate and multivariate survival analyses using Cox regression
| Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| Parameter | n | HR | 95% CI | P-value | HR | 95% CI | p-value |
| PDPN in CAFs | |||||||
| High/low | 31/28 | 0.92 | (0.53-1.57) | 0.75 | |||
| PDPN in TCs | |||||||
| High/low | 25/34 | 0.90 | (0.52-1.56) | 0.71 | |||
| Concordant PDPN | |||||||
| Yes/no | 35/24 | 2.63 | (1.44-4.79) | 0.0017 | 3.62 | (1.69-7.77) | 0.00094 |
| pT | |||||||
| T3-4/T1-2 | 50/9 | 3.79 | (1.47-9.76) | 0.0058 | 3.45 | (1.27-9.35) | 0.015 |
| pN | |||||||
| N1-3/N0 | 30/29 | 1.22 | (0.71-2.10) | 0.47 | |||
| pM | |||||||
| M1/M0 | 5/54 | 1.48 | (0.58-3.81) | 0.41 | |||
| cT | |||||||
| T3-4/T1-2 | 34/16 | 1.38 | (0.72-2.64) | 0.33 | |||
| cN | |||||||
| N1-3/N0 | 33/14 | 2.41 | (1.17-4.98) | 0.017 | 1.94 | (0.92-4.11) | 0.084 |
| cM | |||||||
| M1/M0 | 3/42 | 0.91 | (0.28-2.98) | 0.87 | |||
| Tumor grade | |||||||
| G3/G1-2 | 12/47 | 0.82 | (0.42-1.59) | 0.55 | |||
| Age at diagnosis | |||||||
| ≥ 56/< 56 | 33/26 | 0.80 | (0.46-1.39) | 0.43 | |||
| Pre-Op CCRT | |||||||
| Yes/no | 42/17 | 1.12 | (0.61-2.08) | 0.72 | |||
HR = hazard ratio; 95% CI = 95% confidence interval; PDPN = podoplanin; CAFs = cancer-associated fibroblasts; TCs = tumor cells; Concordant PDPN = concordant expression of podoplanin in cancer-associated fibroblasts and tumor cells; Pre-Op CCRT = pre-operative concurrent chemoradiotherapy.